AstraZeneca’s Qtrilmet Receives CHMP’s Recommendation for its Approval to Treat Patients with Type-2 Diabetes in Europe

AstraZeneca Announces Acceptance of Priority Review of Lynparza’s (olaparib) sNDA by FDA in Patients with BRAC-Mutated Advance Ovarian Cancer


  • The CHMP’s positive opinion is based on five P-III studies assessing Forxiga (dapagliflozin) + Onglyza (saxagliptin) + Metformin vs the Forxiga + Metformin/Onglyza + Metformin/Glimepiride/Metformin in patients with inadequately controlled T2D
  • The P-III studies results demonstrated that Qtrilmet resulted in a reduction of HbA1c and is not inferior to the combined use of insulin and metformin with or without SU in reducing HbA1c
  • Qtrilmet is a combination of SGLT2 inhibitor, DPP‑4 inhibitor & metformin hydrochloride extended release and is approved under the name Qternmet XR as an adjunct to diet and exercise to improve glycemic control in adults with T2D in the US

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Pharmaceutical Technology